Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

(marketscreener.com) Data to be discussed in a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer SymposiumPreliminary Phase 2 results from ACE-Breast-03 study demonstrate 57.1% confirmed overall response rate by RECIST v1.1 and 100% disease control rate in heavily pre-treated patients with HER2 positive metastatic breast cancer following...https://www.marketscreener.com/quote/stock/AMBRX-BIOPHARMA-INC-123776315/news/Ambrx-Announces-Encouraging-Preliminary-Safety-and-Efficacy-Data-Evaluating-ARX788-in-HER2-Positive-42514577/?utm_medium=RSS&utm_content=20221209